Area of research
Hematology · Genetics
Research interest
Research interests include Multiple Myeloma Research and Treatments, Chronic Lymphocytic Leukemia Research, Chronic Myeloid Leukemia Treatments, and Myeloproliferative Neoplasms: Diagnosis and Treatment.
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <scp>ELOQUENT</scp>‐2 follow‐up and <i>post‐hoc</i> analyses on progression‐free survival and tumour growth
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up
ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).